Cardiology
4 articles on Cardiology, written by Shotlee and medically reviewed for clinical accuracy.
GLP-1 Therapies: Australia's New Blueprint for Obesity and Heart Health
Australia has released a groundbreaking clinical consensus statement on obesity and cardiovascular disease (CVD), marking a pivotal moment in medical practice. This new guidance places GLP-1 receptor agonists—a class of medications including semaglutide and tirzepatide—at the forefront of treatment strategies, offering clinicians a clear, practical pathway for improving patient outcomes.
6 min read
Tirzepatide & Semaglutide: Groundbreaking Heart Protection
A recent study has provided real-world evidence of the cardiovascular benefits of tirzepatide, a dual GLP-1 and GIP receptor agonist. The research compared tirzepatide to semaglutide and sitagliptin, finding similar heart protection.
2 min read
Cardioprotection Comparison: GLP-1 Drugs Show Similar Effects
Research comparing tirzepatide and semaglutide shows both medications reduce the risk of major cardiovascular events. The study highlights the early onset of cardioprotective effects, suggesting mechanisms beyond just weight loss. These findings support the integration of both agents into cardiovascular clinical practice.
2 min read
Real-World Data Highlights Heart Benefits of Diabetes Drugs Semaglutide and Tirzepatide
New research indicates that semaglutide and tirzepatide, drugs used for managing type 2 diabetes, exhibit heart-protective effects in real-world settings, mirroring findings from clinical trials. The study highlights the cardiovascular benefits these medications offer to patients in everyday clinical practice.
4 min read